Biologics and Small-Molecule Inhibitors for the Treatment of Nummular Eczema: A Systematic Review.

J Drugs DermatolOct 1, 2026
Clinical ResearchDermatology

Lucie Joerg, Julia Stolyar, Jared Jagdeo

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluated the efficacy of biologics and small-molecule inhibitors for treating nummular eczema (NE) by analyzing 10 studies. The findings support dupilumab and tralokinumab as effective treatments (Grade B), while roflumilast and delgocitinib are recommended for select cases (Grade C), and apremilast is not recommended.

Key findings

  • Dupilumab and tralokinumab received a Grade B recommendation for NE treatment.
  • Roflumilast and delgocitinib are recommended for selected cases with a Grade C.
  • Apremilast is not recommended for the treatment of nummular eczema.

Why it matters

Nummular eczema lacks FDA-approved therapies, making the identification of effective treatments crucial for managing this chronic condition and improving patient quality of life.

Source

PubMed · PMID 42826139

Published in J Drugs Dermatol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Dermatology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.